Stock Report

All about this stock under one free report Last Updated: 15-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Nymox Pharmaceutical Corporation (Bahamas) - ADR Key Ratios

Stock Card factsheet share-fund-plan-icon

$0.47

up-down-arrow $-0.06 (-11.77%)

As on 07-Sep-2023 09:30EDT

Market cap

info icon

$18 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

48

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -165.75 37.96 105.95 27.50 15.54
Net Profit 75.24 -124.92 -71.53 -2.81 2.09
EPS -- -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-22Dec-21
EBIT-Margin info -234,400.00-83,140.62------
Net Margin info ---3,543.14------
Return on equity info -208.56-249.35--1,330.16-1,534.59
Return on Capital info 564.44215.16--3,099.53-1,024.10
Return on Assets info -367.56-306.26-229.69-428.36-434.70
Debt to Equity (x) info ----0.00-0.36-0.77

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
3,099.53
-1,024.10
-382.10
-249.13
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
1,330.16
-1,534.59
-421.24
-252.63
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-229.69

--

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
-229.69
-428.36
-434.70
-239.63
-194.62
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
--
-234,400.00
-11,487.07
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
--
-235,600.00
-11,379.31
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
-1.00
-0.96
-0.61
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

105.95

--

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
105.95
46.80
-6.69
12.05
-26.08
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-71.53

--

Year on year growth in profit after tax

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
-71.53
47.75
-6.76
10.76
-24.60
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
-0.36
-0.77
0.20
0.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

-0.28

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
-0.28
-0.36
-0.45
0.03
0.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.07

--

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
0.07
0.69
0.58
2.13
2.61
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.06

--

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
0.06
0.68
0.56
2.11
2.60
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

0.13

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
0.13
-154.70
-320.62
-279.05
-350.66
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
--
400.00
15.52
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
--
0.00
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
--
1,387.95
50.38
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
--
2,602.41
201.52
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
--
138,429.75
7,673.40
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
--
-134,439.39
-7,421.50
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Book Value

48.02

--

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
48.02
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-3.19

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
-3.19
0.20
0.04
0.28
0.41
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

18

--

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Nymox Pharmaceutical Corporation (Bahamas) - ADR
18
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...